A Harvard Medical School-led team has shown that a soluble form of FLT1 causes about one-third of peripartum cardiomyopathy cases-those associated with preeclampsia. Ongoing studies are seeking to identify small molecule inhibitors of the protein and determine whether the mechanism also underlies the other two-thirds of cases.